Resilient T cell responses to B.1.1.529 (Omicron) SARS-CoV-2 variant

Mladen Jergovic; Christopher P Coplen; Jennifer L Uhrlaub; Shawn C Beitel; Jefferey L Burgess; Karen Lutrick; Katherine D Ellingson; Makiko Watanabe; Janko Nikolich-Zugich.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-22269361

Documentos relacionados

  1. Cutting Edge: T Cell Responses to B.1.1.529 (Omicron) SARS-CoV-2 Variant Induced by COVID-19 Infection and/or mRNA Vaccination Are Largely Preserved.
  2. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses.
  3. Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study.
  4. T cell responses to SARS-CoV-2 spike cross-recognize Omicron.
  5. Memory CD8<sup>+</sup> T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination.
  6. Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants.
  7. Measurement of IFN-γ and IL-2 for the assessment of the cellular immunity against SARS-CoV-2.
  8. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.
  9. Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.
  10. Synergism of CD28 Immune Molecule in Late Immunosuppressive Phase of COVID-19: Effectiveness in Vaccinated Individuals.